Powder: -20°C for 3 years | In solvent: -80°C for 1 year
4E1RCat 是 cap 依赖性翻译抑制剂,可抑制 eIF4 g 与 eIF4E 的结合,IC50 为 3.2 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 385 | 现货 | ||
5 mg | ¥ 667 | 现货 | ||
10 mg | ¥ 919 | 现货 | ||
50 mg | ¥ 2,098 | 现货 | ||
100 mg | ¥ 3,758 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 727 | 现货 |
产品描述 | 4E1RCat is a dual inhibitor of eIF4E:eIF4 g and eIF4E:4E-BP1 interaction. And it inhibits the binding of eIF4 g to eIF4E with IC50 of 3.2 μM. |
靶点活性 | eIF4 g:3.2 μM |
激酶实验 | Kinase Assay: GSK3 scintillation proximity assay is done. The competition experiments are carried out in duplicate with 10 concentrations of the inhibitor in clear-bottomed microtiter plates. The biotinylated peptide substrate biotin-AAEELDSRAGS(PO3H2)PQL, is added at a final concentration of 2 μM in an assay buffer containing 6 milliunits of recombinant human GSK3 (equal mix of both α and β), 12 mM MOPS, pH 7.0, 0.3 mM EDTA, 0.01% β-mercaptoethanol, 0.004% Brij 35, 0.5% glycerol, and 0.5 μg of bovine serum albumin/25 μl and preincubated for 10–15 min. The reaction is initiated by the addition of 0.04 μCi of [γ-33P]ATP and unlabeled ATP in 50 mM Mg(Ac)2 to a final concentration of 1 μM ATP and assay volume of 25 μl. Blank controls without peptide substrate are used. After incubation for 20 min at room temperature, each reaction is terminated by the addition of 25 μl of stop solution containing 5 mM EDTA, 50 μM ATP, 0.1% Triton X-100, and 0.25 mg of streptavidin-coated SPA beads corresponding to 35 pmol of binding capacity. After 6 h the radioactivity is determined in a liquid scintillation counter. |
分子量 | 478.45 |
分子式 | C28H18N2O6 |
CAS No. | 328998-25-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 23.9 mg/mL (50 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0901 mL | 10.4504 mL | 20.9008 mL | 52.2521 mL |
5 mM | 0.418 mL | 2.0901 mL | 4.1802 mL | 10.4504 mL | |
10 mM | 0.209 mL | 1.045 mL | 2.0901 mL | 5.2252 mL | |
20 mM | 0.1045 mL | 0.5225 mL | 1.045 mL | 2.6126 mL | |
50 mM | 0.0418 mL | 0.209 mL | 0.418 mL | 1.045 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
4E1rcat 328998-25-0 Apoptosis Autophagy PERK inhibit Inhibitor 4E-1rcat Eukaryotic Initiation Factor (eIF) inhibitor